Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD

Clinical trial NCT02165826 · COMPLETED

Trial details

NCT number: NCT02165826
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Obstructive Pulmonary Disease (COPD)

Start date: 2014-05-01
Primary completion: 2015-09-01
Enrollment: 1323

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.